Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib and Temsirolimus in HER2-mutant NSCLC
NCT01827267Phase 2Completed
- Sponsor
- Puma Biotechnology, Inc.
- Start
- Jul 2013
- Primary completion
- Sep 2016
- Countries
- 2
01
Overview
A Phase 2 trial of neratinib in non-small cell lung cancer (NSCLC), sponsored by Puma Biotechnology, Inc.. Started Jul 2013; status: completed.
02
Drugs
neratinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01827267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01827267.